Medical Xpress - latest medical and health news stories
Darolutamide slows spread of castration-resistant prostate cancer
Tue, 19 Feb 2019 13:10:01 EST
(HealthDay)—Metastasis-free survival is significantly longer among men with nonmetastatic, castration-resistant prostate cancer treated with darolutamide versus placebo, according to a phase 3 study published online Feb. 14 in the New England Journal of Medicine to coincide with the American Society of Clinical Oncology annual Genitourinary Cancers Symposium, held from Feb. 14 to 16 in San Francisco.
